Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Liraglutide as additional treatment for type 1 diabetes.

Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P.

Eur J Endocrinol. 2011 Jul;165(1):77-84. doi: 10.1530/EJE-11-0330. Epub 2011 Jun 6.

2.

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

Kuhadiya ND, Malik R, Bellini NJ, Patterson JL, Traina A, Makdissi A, Dandona P.

Endocr Pract. 2013 Nov-Dec;19(6):963-7. doi: 10.4158/EP13065.OR.

PMID:
23807520
3.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Kielgast U, Krarup T, Holst JJ, Madsbad S.

Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18.

4.

Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.

Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S.

Diabetes Metab Syndr. 2015 Jan-Mar;9(1):30-3. doi: 10.1016/j.dsx.2014.04.034. Epub 2014 May 22. Erratum in: Diabetes Metab Syndr. 2015 Jul-Sep;9(3):200.

PMID:
25605673
5.

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.

Lane W, Weinrib S, Rappaport J, Hale C.

Diabetes Obes Metab. 2014 Sep;16(9):827-32. doi: 10.1111/dom.12286. Epub 2014 Mar 25.

PMID:
24589127
6.

Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.

Arakawa M, Ebato C.

Diabetes Metab Syndr. 2013 Oct-Dec;7(4):223-5. doi: 10.1016/j.dsx.2013.10.002. Epub 2013 Nov 15.

PMID:
24290089
7.
8.
9.

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.

Lane W, Weinrib S, Rappaport J.

Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.

PMID:
21406014
10.

[The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].

Yan L, Wang S, Chen P, Chen C, Shao Z, Xu X, Huang Q.

Zhonghua Nei Ke Za Zhi. 2015 Apr;54(4):307-12. Chinese.

PMID:
26268058
11.

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.

D'Alessio D, Häring HU, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain MP, Vincent M, Pilorget V, Yki-Järvinen H; EAGLE Investigators.

Diabetes Obes Metab. 2015 Feb;17(2):170-8. doi: 10.1111/dom.12406. Epub 2014 Dec 7.

PMID:
25359159
12.

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2012 Sep 14;11:107.

13.

Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.

Pantalone KM, Faiman C.

Diabetes Technol Ther. 2013 Apr;15(4):342-3. doi: 10.1089/dia.2012.0328. Epub 2013 Feb 4.

PMID:
23379638
14.

Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study.

Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2011 Nov;13(11):1139-44. doi: 10.1089/dia.2011.0137. Epub 2011 Aug 30.

PMID:
21877924
15.

Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.

Pieber TR, Deller S, Korsatko S, Jensen L, Christiansen E, Madsen J, Heller SR.

Diabetes Obes Metab. 2015 Aug;17(8):742-50. doi: 10.1111/dom.12473. Epub 2015 May 20.

PMID:
25855340
16.

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.

Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S.

Diabetes Care. 2015 Dec;38(12):2250-7. doi: 10.2337/dc15-1037. Epub 2015 Oct 20.

PMID:
26486191
17.

Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).

Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Torffvit O, Pehrsson NG.

Prim Care Diabetes. 2015 Feb;9(1):15-22. doi: 10.1016/j.pcd.2014.07.010. Epub 2014 Aug 28.

PMID:
25175385
18.

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M.

Intern Med. 2013;52(10):1029-34. Epub 2013 May 15.

19.

Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.

Lapolla A, Frison V, Bettio M, Dal Pos M, Rocchini P, Panebianco G, Tadiotto F, Da Tos V, D'Ambrosio M, Marangoni A, Ferrari M, Pianta A, Balzano S, Confortin L, Lamonica M, Marin N, Strazzabosco M, Brun E, Mesturino CA, Simoncini M, Zen F, Bax G, Bonsembiante B, Cardone C, Dal Frà MG, Gallo A, Masin M, Piarulli F, Sartore G, Simioni N.

Clin Ther. 2015 Mar 1;37(3):574-84. doi: 10.1016/j.clinthera.2014.11.015. Epub 2015 Jan 24.

PMID:
25626486
20.

GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.

Crisci I, Aragona M, Politi KS, Daniele G, Del Prato S.

Acta Diabetol. 2015 Dec;52(6):1129-33. doi: 10.1007/s00592-015-0800-6. Epub 2015 Aug 21.

PMID:
26293127

Supplemental Content

Support Center